GlobeNewswire Inc.Jun 23, 1:00 PM ET▲ Positive
Recently initiated Phase I clinical trial of AKB-9090 (HIF-PH inhibitor) for cardiac surgery-associated AKI in April 2026, demonstrating active pipeline progression.
Akebia Therapeutics news
$0.8861−0.78%
Close Sep 29, 2026 · split-adjustedArticles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0
About Akebia Therapeutics
No recent articles focused on Akebia Therapeutics.
Also mentions AKBA
Articles that tag AKBA but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology